Cardiovascular disease is the number one cause of death in the western world. In this field, there is a growing understanding that anti-inflammatory treatments can have a beneficial effect leading to a lower mortality in different types of heart patients. Many of the existing anti-inflammatory treatments come at the cost of a suppressed ability for the body to fight infectious diseases and it is difficult to balance the good and the bad. We invested in Athera because of their pioneering research originated at the Karolinska Institute in Stockholm, leading to a fully human monoclonal antibody, ATH3G10, that binds to oxidized phospholipid, also called Phosphoryl choline (PC). PC is exposed in blood vessels in vascular disease such as atherosclerosis. ATH3G10 has the potential to become a First-in-Class drug for broad use in cardiovascular disease. Athera’s lead program is a Phase 2 clinical study in high risk myocardial infarction patients.